连遭3个跌停！“前10倍牛”人气骤降，多只高标陷入回撤，这些也遭“亏钱效应”

Core Viewpoint - The stock of Shuangcheng Pharmaceutical has experienced a significant decline, recording three consecutive trading halts, with a drop of nearly 30% from its recent peak, attributed to poor performance and potential delisting concerns [3][5]. Group 1: Stock Performance - Shuangcheng Pharmaceutical's stock price has hit a new low over the past week, closing with a drop limit today, and has seen a total of 4.2 billion yuan in sell orders, accounting for approximately 10.75% of its total circulating shares [1]. - The stock had previously surged nearly 87.2% over eight trading days from April 9 to April 18, but has since faced a sharp decline due to disappointing earnings [3]. - The cumulative trading volume during the three consecutive trading halts from April 21 to April 23 was only 2.8 billion yuan, which is two-thirds of the sell order amount on the latest trading halt [3]. Group 2: Market Context - As of April 23, a total of 35 stocks in the Shanghai, Shenzhen, and Beijing markets have hit their trading limits, marking the highest number of trading halts in nearly two weeks since April 8, with 19 of these being non-ST stocks [5]. - The sectors most affected by trading halts include pharmaceuticals, food and beverage, textiles, basic chemicals, retail, defense, and environmental protection [5]. - Among the stocks experiencing declines, Shuangcheng Pharmaceutical has recorded three consecutive trading halts, while other stocks like Nanhua Biological and Xingguang Co. have seen two consecutive halts [7]. Group 3: Trading Data - On April 22, the top buying and selling firms for Shuangcheng Pharmaceutical included China Galaxy Securities and Huaxin Securities, with significant buy orders from specific trading desks [4]. - Historical data indicates that in the past year, 463 stocks have recorded consecutive trading halts, with 83 stocks experiencing three or more halts, representing nearly 17.9% of the total [4].